These diverse strategies allow fine-tuned dissection of CDK12/13 biology and offer multiple routes to pharmacologically induce “BRCAness,” enhance PARP-inhibitor sensitivity, and overcome transcriptional therapy resistance across cancer types (Table 1). Here, CDK12 is linked to cancer.